NASDAQ:CRME
TSX:COM
VANCOUVER, June 23, 2017 /PRNewswire/ - Cardiome Pharma
Corp. (NASDAQ: CRME / TSX: COM) today announced the results of
voting at its 2017 Annual General and Special Meeting of
Shareholders held on June 20,
2017.
A total of 24,583,372 common shares were voted in
connection with the meeting, representing approximately 77.00% of
the issued and outstanding common shares of the company.
Shareholders voted as follows:
Election of Directors
By resolution passed by ballot vote, the following six nominees
proposed by management were elected as directors of Cardiome to
hold office until the next annual meeting of Shareholders or until
their successors are elected or appointed:
Nominee
|
Votes For
|
% Votes
For
|
Votes
Withheld
|
% Votes
Withheld
|
Richard M.
Glickman
|
14,080,137
|
87.60%
|
1,992,340
|
12.40%
|
W. James
O'Shea
|
15,466,194
|
96.23%
|
606,283
|
3.77%
|
William L.
Hunter
|
15,543,529
|
96.71%
|
528,948
|
3.29%
|
Mark H.
Corrigan
|
15,465,791
|
96.23%
|
606,686
|
3.77%
|
Arthur H.
Willms
|
15,543,282
|
96.71%
|
529,195
|
3.29%
|
Robert J.
Meyer
|
15,544,284
|
96.71%
|
528,193
|
3.29%
|
Appointment of Auditor
By resolution passed by show of hands, KMPG LLP, Chartered
Accountants, was appointed auditor of the company for the ensuing
year.
Approval of Amendments to and Unallocated Entitlements under
the Restricted Share Unit Plan
By resolution passed by ballot vote, amendments to the Company's
Restricted Share Unit Plan were ratified, confirmed and approved,
and the Restricted Share Unit Plan was re-approved and all
unallocated entitlements under the Restricted Share Unit Plan were
approved, and the Company was granted the ability to continue
granting restricted share units under the Restricted Share Unit
Plan until June 20, 2020.
Votes For
|
% Votes
For
|
Votes
Against
|
% Votes
Against
|
9,164,437
|
57.02%
|
6,908,040
|
42.98%
|
Approval of Amendments to and Unallocated Options under the
Incentive Stock Option Plan
By resolution passed by ballot vote, amendments to the Company's
Incentive Stock Option Plan were ratified, confirmed and approved
and all unallocated options under the Incentive Stock Option Plan
were approved, and the Company was granted the ability to continue
granting options under the Incentive Stock Option Plan until
June 20, 2020.
Votes For
|
% Votes
For
|
Votes
Against
|
% Votes
Against
|
14,004,680
|
87.13%
|
2,067,797
|
12.87%
|
About Cardiome Pharma Corp.
Cardiome Pharma Corp. is a
specialty pharmaceutical company dedicated to the development and
commercialization of innovative therapies that will improve the
quality of life and health of patients suffering from disease.
Cardiome has two marketed, in-hospital, cardiology products,
BRINAVESS® (vernakalant IV), approved in Europe, Canada, and other territories for the rapid
conversion of recent onset atrial fibrillation to sinus rhythm in
adults, and AGGRASTAT® (tirofiban HCl) a reversible GP
IIB/IIIa inhibitor indicated for use in patients with acute
coronary syndrome. Cardiome also commercializes
ESMOCARD® and ESMOCARD LYO® (esmolol
hydrochloride), a short-acting beta-blocker used to control rapid
heart rate in a number of cardiovascular indications, on behalf of
their partner Amomed in select European markets. Cardiome has also
licensed: XYDALBA™ (dalbavancin hydrochloride), a second
generation, semi-synthetic lipoglycopeptide approved in the EU for
the treatment of acute bacterial skin and skin structure infections
(ABSSSI) in adults for select European and Middle Eastern nations
and Canada from Allergan; and
TREVYENT®, a development stage drug device combination
that is under development for Pulmonary Arterial Hypertension for
Europe, the Middle East and for Canadian markets from
SteadyMed Therapeutics.
Cardiome is traded on the NASDAQ Capital Market (CRME) and the
Toronto Stock Exchange (COM). For more information, please visit
our web site at www.cardiome.com.
Forward-Looking Statement Disclaimer
Certain
statements in this news release contain forward-looking statements
within the meaning of the Private Securities Litigation Reform Act
of 1995 or forward-looking information under applicable Canadian
securities legislation that may not be based on historical fact,
including without limitation statements containing the words
"believe", "may", "plan", "will", "estimate", "continue",
"anticipate", "intend", "expect" and similar expressions.
Forward-looking statements may involve, but are not limited to,
comments with respect to our objectives and priorities for 2017 and
beyond, our strategies or future actions, our targets, expectations
for our financial condition and the results of, or outlook for, our
operations, research and development and product and drug
development. Such forward-looking statements involve known and
unknown risks, uncertainties and other factors that may cause the
actual results, events or developments to be materially different
from any future results, events or developments expressed or
implied by such forward-looking statements. Many such known risks,
uncertainties and other factors are taken into account as part of
our assumptions underlying these forward-looking statements and
include, among others, the following: general economic and business
conditions in the United States,
Canada, Europe, and the other regions in which we
operate; market demand; technological changes that could impact our
existing or future products; competition; existing governmental
legislation and regulations and changes in, or the failure to
comply with, governmental legislation and regulations; availability
of financial reimbursement coverage from governmental and
third-party payers for products and related treatments; adverse
results or unexpected delays in pre-clinical and clinical product
development processes; adverse findings related to the safety
and/or efficacy of our products or products; decisions, and the
timing of decisions, made by health regulatory agencies regarding
approval of our technology and products; the requirement for
substantial funding to expand commercialization activities; and any
other factors that may affect our performance. In addition, our
business is subject to certain operating risks that may cause any
results expressed or implied by the forward-looking statements in
this presentation to differ materially from our actual results.
These operating risks include: our ability to attract and retain
qualified personnel; our ability to successfully complete
pre-clinical and clinical development of our products; changes in
our business strategy or development plans; intellectual property
matters, including the unenforceability or loss of patent
protection resulting from third-party challenges to our patents;
market acceptance of our technology and products; our ability to
successfully manufacture, market and sell our products; the
availability of capital to finance our activities. These and other
risks are described in the Form 40F and associated documents filed
March 29, 2017 (see for example,
"Risk Factors" in the Annual Information Form for the year ended
December 31, 2016), in the Form 6-K
filed May 15, 2017, and in our other
filings with the Securities and Exchange Commission ("SEC")
available at www.sec.gov and the Canadian securities regulatory
authorities at www.sedar.com. Given these risks, uncertainties and
factors, you are cautioned not to place undue reliance on such
forward-looking statements and information, which are qualified in
their entirety by this cautionary statement. All forward-looking
statements and information made herein are based on our current
expectations and we undertake no obligation to revise or update
such forward-looking statements and information to reflect
subsequent events or circumstances, except as required by law.
SOURCE Cardiome Pharma Corp.